Total Payments
$58,692
2024 Payments
$34.13
Companies
22
Transactions
288
Medicare Patients
570
Medicare Billing
$51,833
Payment Breakdown by Category
Research$47,713 (81.3%)
Food & Beverage$5,798 (9.9%)
Travel$4,241 (7.2%)
Other$940.00 (1.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $47,713 | 9 | 81.3% |
| Food and Beverage | $5,798 | 262 | 9.9% |
| Travel and Lodging | $4,241 | 16 | 7.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $940.00 | 1 | 1.6% |
Payments by Type
Research
$47,713
9 transactions
General
$10,979
279 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Valneva Austria GmbH | $33,602 | 2 | $0 (2022) |
| PFIZER INC. | $12,112 | 63 | $0 (2020) |
| Biogen, Inc. | $7,903 | 1 | $0 (2019) |
| Eli Lilly and Company | $2,068 | 4 | $0 (2023) |
| Amgen Inc. | $938.53 | 58 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $899.84 | 65 | $0 (2020) |
| Horizon Pharma plc | $235.00 | 21 | $0 (2018) |
| Janssen Biotech, Inc. | $212.00 | 24 | $0 (2018) |
| Lilly USA, LLC | $130.26 | 8 | $0 (2020) |
| UCB, Inc. | $111.53 | 9 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $34.13 | 1 | Merck Sharp & Dohme LLC ($34.13) |
| 2023 | $316.33 | 2 | Eli Lilly and Company ($300.00) |
| 2022 | $34,776 | 5 | Valneva Austria GmbH ($33,602) |
| 2021 | $671.59 | 2 | Eli Lilly and Company ($626.59) |
| 2020 | $4,320 | 12 | PFIZER INC. ($4,140) |
| 2019 | $11,637 | 65 | Biogen, Inc. ($7,903) |
| 2018 | $4,322 | 105 | PFIZER INC. ($3,290) |
| 2017 | $2,614 | 96 | PFIZER INC. ($1,661) |
All Payment Transactions
288 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/05/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $34.13 | General |
| Category: VACCINE | ||||||
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $300.00 | Research |
| Study: A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | ||||||
| 01/24/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.33 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/16/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $4,241.58 | Research |
| Study: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | ||||||
| 06/27/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $29,360.00 | Research |
| Study: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | ||||||
| 06/15/2022 | Merck Sharp & Dohme LLC | CAPVAXIVE (Biological) | Food and Beverage | In-kind items and services | $33.91 | General |
| Category: VACCINE | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $450.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 04/05/2022 | Eli Lilly and Company | — | — | In-kind items and services | $691.00 | Research |
| Study: A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | ||||||
| 06/03/2021 | Bausch Health US, LLC | — | Food and Beverage | In-kind items and services | $45.00 | General |
| 03/24/2021 | Eli Lilly and Company | — | — | In-kind items and services | $626.59 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 10/25/2020 | PFIZER INC. | — | — | In-kind items and services | $940.00 | Research |
| Study: PNEUMOCOCCAL CONJ PNG CLINICAL PUBLICATION PROGRAM | ||||||
| 10/09/2020 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $18.83 | General |
| Category: Diabetes | ||||||
| 09/18/2020 | Lilly USA, LLC | REYVOW (Drug) | Food and Beverage | In-kind items and services | $20.98 | General |
| Category: Neuroscience | ||||||
| 06/24/2020 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $23.28 | General |
| Category: Inflammation | ||||||
| 03/20/2020 | PFIZER INC. | — | — | In-kind items and services | $3,200.00 | Research |
| Study: PNEUMOCOCCAL CONJ PNG CLINICAL PUBLICATION PROGRAM | ||||||
| 02/27/2020 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $16.97 | General |
| Category: Immunology | ||||||
| 02/21/2020 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $21.06 | General |
| Category: KRYSTEXXA | ||||||
| 02/20/2020 | Amgen Inc. | Enbrel (Biological), Prolia | Food and Beverage | In-kind items and services | $13.80 | General |
| Category: Inflammation | ||||||
| 02/18/2020 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $16.16 | General |
| Category: Inflammation | ||||||
| 01/27/2020 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $16.64 | General |
| Category: Immunology | ||||||
| 01/23/2020 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $18.83 | General |
| Category: Inflammation | ||||||
| 01/17/2020 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $13.90 | General |
| Category: Immunology | ||||||
| 12/13/2019 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $11.55 | General |
| Category: Immunology | ||||||
| 12/05/2019 | Amgen Inc. | Enbrel (Biological), Prolia | Food and Beverage | In-kind items and services | $13.00 | General |
| Category: Inflammation | ||||||
| 12/04/2019 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $15.41 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | Valneva Austria GmbH | $33,602 | 2 |
| A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities | Biogen, Inc. | $7,903 | 1 |
| PNEUMOCOCCAL CONJ PNG CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,140 | 2 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $1,077 | 2 |
| A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | Eli Lilly and Company | $691.00 | 1 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $300.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 4 | 280 | 474 | $63,828 | $28,782 |
| 2020 | 3 | 290 | 533 | $55,874 | $23,051 |
Total Patients
570
Total Services
1,007
Medicare Billing
$51,833
Procedure Codes
7
All Medicare Procedures & Services
7 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 126 | 237 | $36,921 | $17,670 | 47.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 117 | 200 | $22,169 | $10,159 | 45.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 23 | 23 | $3,275 | $606.43 | 18.5% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 14 | 14 | $1,463 | $347.15 | 23.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 151 | 312 | $28,413 | $11,068 | 39.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 100 | 175 | $23,275 | $10,282 | 44.2% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 39 | 46 | $4,186 | $1,700 | 40.6% |
About Dr. Carl Griffin, M.D
Dr. Carl Griffin, M.D is a Family Medicine healthcare provider based in Oklahoma City, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2005. The National Provider Identifier (NPI) number assigned to this provider is 1003813825.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Carl Griffin, M.D has received a total of $58,692 in payments from pharmaceutical and medical device companies, with $34.13 received in 2024. These payments were reported across 288 transactions from 22 companies. The most common payment nature is "" ($47,713).
As a Medicare-enrolled provider, Griffin has provided services to 570 Medicare beneficiaries, totaling 1,007 services with total Medicare billing of $51,833. Data is available for 2 years (2020–2021), covering 7 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Oklahoma City, OK
- Active Since 07/07/2005
- Last Updated 04/20/2015
- Taxonomy Code 207Q00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1003813825
Products in Payments
- PREVNAR - 13 (Biological) $2,071
- Enbrel (Biological) $912.86
- ORENCIA (Biological) $899.84
- XELJANZ (Drug) $391.65
- RAYOS (Drug) $184.53
- SIMPONI ARIA (Biological) $175.78
- Cimzia (Drug) $111.53
- Otezla (Drug) $95.48
- KRYSTEXXA (Drug) $50.47
- FORTEO (Drug) $46.22
- BENLYSTA (Biological) $45.77
- FARXIGA (Drug) $42.77
- STELARA (Biological) $36.22
- COSENTYX (Biological) $36.18
- JARDIANCE (Drug) $34.41
- CAPVAXIVE (Biological) $33.91
- JANUVIA (Drug) $33.09
- EVENITY (Biological) $25.67
- KRYSTEXXA (Biological) $21.06
- REYVOW (Drug) $20.98
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Oklahoma City
Melinda Cail, M.d, M.D
Family Medicine — Payments: $96,253
Family Medicine $96,253
Dr. John Pittman, M.d, M.D
Family Medicine — Payments: $58,571
Family Medicine $58,571
Dr. Tyler Phillips, Md, MD
Family Medicine — Payments: $33,490
Family Medicine $33,490
Terrence Truong, M.d, M.D
Family Medicine — Payments: $31,884
Family Medicine $31,884
Jonathan Knox, D.o, D.O
Family Medicine — Payments: $23,297
Family Medicine $23,297
Stanley Corley, M.d, M.D
Family Medicine — Payments: $19,788
Family Medicine $19,788